产品名称 |
LAMA-84人急变期慢性粒细胞白血病细胞 |
货号 |
ZQ0514 |
产品介绍 |
LAMA-84 细胞系是从一名慢性粒细胞白血病急性期患者的外周血中建立的。该患者在 1979-1984 年间接受过白消安治疗;爆发危机发生在 1984 年 3 月末。细胞表达巨核细胞和红细胞标志物,并对 DMSO、TPA、丁酸盐、血红素诱导的分化作出反应。该细胞系的特点是存在费城染色体,导致BCR-ABL融合基因,这是CML的标志。BCR-ABL癌基因以其增加酪氨酸激酶活性的作用而闻名,酪氨酸激酶活性促进各种信号通路,导致不受控制的细胞增殖和对凋亡的抵抗。因此,LAMA-84细胞是研究CML进展的分子机制和评估酪氨酸激酶抑制剂(TKIs)在临床前环境中的疗效的宝贵模型。
在研究中,LAMA-84已被广泛用于了解CML的生物学,特别是在耐药性和疾病进化的背景下。涉及该细胞系的研究有助于阐明对不同代TKIs(如伊马替尼、达沙替尼和尼洛替尼)的细胞反应。此外,LAMA-84还有助于研究克服TKI耐药性的新治疗策略,包括针对受BCR-ABL融合蛋白协同影响的其他信号通路的联合治疗的测试。 |
种属 |
人 |
性别/年龄 |
女性/29岁 |
组织 |
血液 |
疾病 |
慢性髓性白血病 |
生物安全等级 |
BSL-1 |
STR位点信息 |
Amelogenin:X |
细胞类型 |
慢性粒细胞白血病 (CML);巨核细胞 |
形态学 |
圆形细胞 |
生长方式 |
悬浮生长;一些细胞松散贴壁;呈纺锤形 |
倍增时间 |
大约36~50小时 |
培养基和添加剂 |
90%RPMI-1640(中乔新舟 货号:ZQ-200)+10%胎牛血清(中乔新舟 货号:ZQ500-A)+1%双抗(品牌:中乔新舟 货号:CSP006) |
推荐完全培养基货号 |
|
基因表达 |
*** |
保藏机构 |
CLS; 300261/p2498_Lama-84DSMZ; ACC-168Millipore; SCC140 |
供应限制 |
仅供科研使用 |
|
PubMed=3476310
Seigneurin D., Champelovier P., Mouchiroud G., Berthier R., Leroux D., Prenant M., McGregor J., Starck J., Morle F., Micouin C., Pietrantuono A., Kolodie L.
Human chronic myeloid leukemic cell line with positive Philadelphia chromosome exhibits megakaryocytic and erythroid characteristics.
Exp. Hematol. 15:822-832(1987)
PubMed=7996872; DOI=10.1016/0145-2126(94)90102-3
Champelovier P., Valiron O., Jacrot M., Leroux D., Seigneurin D.
Selection and characterization of an erythroeosinophilic subclone (LAMA-87) and an eosinophilic subclone (LAMA-88) from the multipotential cell line LAMA-84.
Leuk. Res. 18:903-918(1994)
PubMed=8693292; DOI=10.1046/j.1365-3083.1996.d01-84.x
Blom T., Nilsson G., Sundstrom C., Nilsson K., Hellman L.
Characterization of a human basophil-like cell line (LAMA-84).
Scand. J. Immunol. 44:54-61(1996)
PubMed=9257809
Champelovier P., Fixe P., Valiron O., Feige J.-J., Praloran V., Seigneurin D.
Proliferation of LAMA-84 and LAMA-87 cell lines is modulated by autocrine loops involving M-CSF and TGF-beta.
Exp. Hematol. 25:958-965(1997)
PubMed=10071072; DOI=10.1016/S0145-2126(98)00171-4
Drexler H.G., MacLeod R.A.F., Uphoff C.C.
Leukemia cell lines: in vitro models for the study of Philadelphia chromosome-positive leukemia.
Leuk. Res. 23:207-215(1999)
PubMed=10576511; DOI=10.1016/s0145-2126(99)00131-9
Uphoff C.C., Habig S., Fombonne S., Matsuo Y., Drexler H.G.
ABL-BCR expression in BCR-ABL-positive human leukemia cell lines.
Leuk. Res. 23:1055-1060(1999)
DOI=10.1016/B978-0-12-221970-2.50457-5
Drexler H.G.
The leukemia-lymphoma cell line factsbook.
(In) ISBN 9780122219702; pp.1-733; Academic Press; London (2001)
PubMed=15843827; DOI=10.1038/sj.leu.2403749
Andersson A., Eden P., Lindgren D., Nilsson J., Lassen C., Heldrup J., Fontes M., Borg A., Mitelman F., Johansson B., Hoglund M., Fioretos T.
Gene expression profiling of leukemic cell lines reveals conserved molecular signatures among subtypes with specific genetic aberrations.
Leukemia 19:1042-1050(2005)
PubMed=16408098; DOI=10.1038/sj.leu.2404081
Quentmeier H., MacLeod R.A.F., Zaborski M., Drexler H.G.
JAK2 V617F tyrosine kinase mutation in cell lines derived from myeloproliferative disorders.
Leukemia 20:471-476(2006)
PubMed=20164919; DOI=10.1038/nature08768
Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S., Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S., Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T., Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.
Signatures of mutation and selection in the cancer genome.
Nature 463:893-898(2010)
PubMed=20809971; DOI=10.1186/1755-8166-3-15
Virgili A., Nacheva E.
Genomic amplification of BCR/ABL1 and a region downstream of ABL1 in chronic myeloid leukaemia: a FISH mapping study of CML patients and cell lines.
Mol. Cytogenet. 3:15.1-15.12(2010)
PubMed=22460905; DOI=10.1038/nature11003
Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J., Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P., Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R., Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Nature 483:603-607(2012)